MAX binding with the variant Rs72780850 in RNA helicase DDX1 for susceptibility to neuroblastoma

September 11, 2020

Neuroblastoma (NB) is the most common solid tumor occurring extracranial diagnosed during childhood, and responds for 15% of all malignancy death in childhood. Although multiple cytotoxic therapies and advanced immunotherapies have been applied, the survival rate of NB remains below 50%. The genetic bases of sporadic NB remains unclear. Achievements are notable, the identified risk variants were only a small proportion of NB association variants. Some functional polymorphisms are missed by DNA chip-based GWAS. Thus, the additional predisposing variants of NB, especially based on various populations, are still needed to be discovered.

"According to the screening strategy of functional gene polymorphism, we have achieved some results. For example, screening strategy designed for polymorphism targeted by MYCN and important functional gene polymorphism sites missed by GWAS chip ". Said Prof. Guo, correspondence of this article. "Colleagues are concerned about why are we focused on the DDX1 gene this time. Interestingly, DDX1 loci locates very close to MYCN gene, it was predicted that it may be cis-regulated by MYCN. And we have found that highly expressed DDX1 is close associated to poor survival of neuroblastoma." Authors revealed genetic variation leading the increased DDX1 expression is associated with susceptibility to neuroblastoma. "MAX is the binding partner of the oncogenic transcription factor MYCN. Its binding affinity to DDX1 promoter rs72780850 C allele is higher than T allele. Interestingly, MYCN can active the reporter activity of DDX1 promoter, but cannot bind to the promoter alone. This result consistants with the way of MYCN working, like all members of the MYC family, requiring interaction with members of the MAX family to form a functional transcription factor." Said Dr. Jin, first author of this work. Their work systematically revealed the relationship between MYCN-related variants and neuroblastoma susceptibility in the Chinese population, and provided mechanisms for how this variant working.
This work was supported by grants from the National Natural Science Foundation of China (81472369 and 81502144), Beijing Natural Science Foundation Program and Scientific Research Key Program of Beijing Municipal Commission of Education (KZ201810025034), Clinical Application Research Funds of Capital Beijing (Z171100001017051), Beihang University & Capital Medical University Advanced Innovation Center for Big Data-Based Precision Medicine Plan (BHME-201804 and BHME-201904), The Special Fund of the Pediatric Medical Coordinated Development Center of Beijing Hospitals Authority (No. XTCX201806).

See the article: Jin, Y., Shi, J., Wang, H., et al. (2020). MYC-Associated Protein X Binding with the Variant Rs72780850 in RNA Helicase DEAD Box 1 for Susceptibility to Neuroblastoma. Sci China Life Sci, in press

Science China Press

Related Neuroblastoma Articles from Brightsurf:

Early trial hints CAR T cells may combat solid tumors in children with neuroblastoma
A phase 1 trial involving 12 children with relapsed neuroblastoma - a hard-to-treat pediatric cancer - shows that anticancer CAR T cells displayed signs of efficacy against these tumors while avoiding damage to nerve tissue.

Researchers mine data and connect the dots about processes driving neuroblastoma
St. Jude Children's Research Hospital scientists lead genome analysis to better understand one of the most common childhood solid tumors.

Promising treatment for aggressive childhood cancer
A drug has shown great promise in the treatment of neuroblastoma, an aggressive form of childhood cancer.

MAX binding with the variant Rs72780850 in RNA helicase DDX1 for susceptibility to neuroblastoma
The researchers adopted the functional polymorphism research strategy to screen out the functional polymorphisms associated with neuroblastoma in Chinese population and elucidate its mechanism, providing data on children susceptible to neuroblastoma in China.

A novel radioisotope therapy for children with neuroblastoma
Researchers from Kanazawa University retrospectively analyzed children with refractory or relapsed high-risk neuroblastoma who were treated with high-dose 131I-metaiodobenzylguanidine at Kanazawa University Hospital.

New method for monitoring residual disease after treatment in children with neuroblastoma
Neuroblastoma is a cancer that affects children, characterized by solid tumors that develop from immature nerve cells.

Research sheds important light on the metastasis of neuroblastoma
Research sheds important light on the metastasis of neuroblastoma.

A step forward in the struggle against neuroblastoma, a type of childhood cancer
A protein called CD44 makes it possible to identify the population of mother cells that are responsible for the aggressive nature and low survival rate of neuroblastoma, a type of childhood cancer that mainly affects children of two and three years old.

More children survive neuroblastoma
Both the survival rate and the incidence of neuroblastoma have increased in the last decennia in the Netherlands, as was shown by a study from the Princess Máxima Center.

TTUHSC researchers publish preclinical data on new drug combination to treat neuroblastoma
Neuroblastoma, the most common cancer outside of the brain in infants and young children, often fails to respond to therapy.

Read More: Neuroblastoma News and Neuroblastoma Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to